# Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

> **NCT02593045** · PHASE1 · COMPLETED · sponsor: **Innate Pharma** · enrollment: 44 (actual)

## Conditions studied

- Cutaneous T-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** IPH4102

## Key facts

- **NCT ID:** NCT02593045
- **Lead sponsor:** Innate Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2020-04
- **Final completion:** 2020-04
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02593045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02593045, "Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02593045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*